glp 1 lean mass loss GLP-1 agonists and changes in body and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis Study finds GLP-1 receptor agonists

Addressing recent docking challenges: a hybrid strategy to integrate template-based and free protein-protein docking

GLP-1 release depends on communication between your gut and brain

Abstract Aims/hypothesis We aimed to determine whether the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) in individuals with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus decreases the risk of new-onset adverse cardiovascular events (CVEs) and mortality rate compared with other glucose-lowering drugs in a real setting at a population level

Role of pancreatic transcription factors in maintenance of mature -cell function

DPP-4 inhibitors for treating diabetes Just as exenatide was making its way to approval for type 2 diabetes, another type of drug had appeared on the scene for the disease

1 2 "Molecular basis of glutathione reductase deficiency in human blood cells"